PK
PKTX.US Protokinetix Inc
- Market cap
- USD 824K
- P/E
- -
- P/B
- 3.33x
- ROE
- -148.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PKTX.US undervalued?
Graham numberThe Graham number of Protokinetix Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Protokinetix Inc fundamental analysis
No fundamental analysis for Protokinetix Inc yet.
Protokinetix Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Protokinetix Inc
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). Its AFGPs are used in various commercial applications, such as targeted health care solutions, as well as AAGPs are used in ophthalmology, dermatology, transplants, and biomanufacturing areas. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKin…
Full company profileProtokinetix Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Protokinetix Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -3.00K | -3.00K | -3.00K | -3.00K | -3.00K | -3.00K | -58.5K | -48.3K | -52.9K | - | - |
| Operating Income | -1.52M | -1.51M | -1.22M | -4.19M | -7.64M | -2.33M | -1.85M | -367K | -311K | -394K | -367K |
| EBITDA | -1.52M | -1.51M | -1.21M | -4.19M | -7.64M | -2.33M | -1.85M | -367K | -311K | -342K | -324K |
| Net Income | -1.52M | -1.51M | -1.22M | -4.20M | -7.64M | -2.33M | -1.91M | -415K | -364K | -394K | -367K |
| EPS | -0.01 | -0.01 | 0.00 | -0.02 | -0.03 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 542K | 518K | 325K | 586K | 469K | 446K | 463K | 481K | 466K | 483K | 485K |
| Total Liabilities | 45.3K | 145K | 78.9K | 25.5K | 45.0K | 93.3K | 41.5K | 44.7K | 124K | 185K | 237K |
| Shareholders' Equity | 497K | 374K | 246K | 560K | 424K | 353K | 421K | 436K | 342K | 298K | 247K |
| Cash & Short-term Investments | 371K | 303K | 136K | 377K | 193K | 57.6K | 25.6K | 20.4K | -4.70K | 1.12K | 524.00 |
| Total Debt | - | 118K | - | - | - | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -820K | -605K | -453K | -851K | -881K | -890K | -805K | -376K | -223K | -135K | -62.2K |
| Capital Expenditure | 29.8K | 59.0K | 35.5K | 25.0K | 70.2K | 91.0K | 132K | 59.2K | 58.1K | 56.3K | 46.2K |
| Free Cash Flow | -850K | -664K | -489K | -876K | -951K | -981K | -937K | -435K | -223K | -192K | -108K |
| Ratios | |||||||||||
| ROE | -306.9% | -405.2% | -494.5% | -749.1% | -1,801.9% | -659.8% | -452.6% | -95.2% | -106.4% | -132.1% | -148.6% |
| ROA | -281.2% | -292.2% | -374.4% | -716.5% | -1,629.2% | -521.9% | -412.0% | -86.4% | -78.1% | -81.4% | -75.8% |
| Debt to Equity | - | 0.31x | - | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Protokinetix Inc dividends
Protokinetix Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 5:2 on Apr 29, 2002.
Who owns Protokinetix Inc
- Insiders 42.89%
- Institutions 0.01%
- Public & others 57.10%
- Shares outstanding 412M
- Free float 235M
Protokinetix Inc company profile
- Company name
- Protokinetix Inc
- Ticker
- PKTX.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 109 W Main St, Dalton, OH, United States, 44618
- Phone
- 330 455 4971
- Website
- protokinetix.com
About Protokinetix Inc
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). Its AFGPs are used in various commercial applications, such as targeted health care solutions, as well as AAGPs are used in ophthalmology, dermatology, transplants, and biomanufacturing areas. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Dalton, Ohio.
Protokinetix Inc management
2- Mr. Michael Richard Guzzetta CPAChairman, CEO, CFO, Treasurer & Secretary · born 1958
- Dr. Keith R. Brunt Ph.D.President & Director · born 1979